本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 证券代码：688606 证券简称：奥泰生物 公告编号：2025-056 杭州奥泰生物技术股份有限公司 关于 2024 年限制性股票激励计划首次授予第一个归 属期归属结果的公告 根据中国证券监督管理委员会、上海证券交易所、中国证券登记结算有限责 任公司上海分公司有关业务规则的规定，杭州奥泰生物技术股份有限公司（以下 简称"公司"）于 2025 年 12 月 11 日收到中国证券登记结算有限责任公司上海 分公司出具的《过户登记确认书》，完成了公司 2024 年限制性股票激励计划（以 下简称"本次激励计划"）首次授予第一个归属期归属的股份登记工作。现将有 关情况公告如下： 一、本次限制性股票归属的决策程序及相关信息披露 （一）2024 年 9 月 2 日，公司召开第三届董事会第七次会议，审议并通过 《关于公司<2024 年限制性股票激励计划（草案）>及其摘要的议案》《关于公 司<2024 年限制性股票激励计划实施考核管理办法>的议案》《关于提请公司股 东大会授权董事 ...

Core Viewpoint - The article discusses the recent sample adjustment of the CSI Dividend Index, highlighting the reasons for the removal and addition of stocks, and the overall impact on the index's quality and dividend yield [3][9]. Sample Adjustment Information and Logic Analysis - The CSI Dividend Index underwent a sample adjustment involving 20 stocks, accounting for 20% of the total sample size [5]. - Stocks were removed primarily due to low dividend yields, liquidity issues, or excessively high payout ratios [6]. - Notably, many stocks were removed because their dividend yields fell below acceptable levels, often due to declining performance [6]. Stocks Removed from the Index - Stocks such as Aotai Biological, Baosteel, and Dashiang were removed due to low dividend yields, with Baosteel's yield at 3.68% and Aotai's at 5.62% [5]. - Other reasons for removal included liquidity issues for companies like Dashiang and Fuanna, and high payout ratios for companies like Huafa and Xiangzhong Energy [5]. Stocks Added to the Index - New additions included stocks like Anhui Construction and Baoxini, which had higher dividend yields, with Anhui's yield at 5.46% [7]. - The adjustment included a diverse range of industries, enhancing the index's overall sector representation [8]. Comparison of Basic Data Before and After Adjustment - The overall financial performance of stocks added to the index was superior to those removed, with net profit growth of -2.94% for new additions compared to -23.52% for those removed [11]. - The return on equity (ROE) for new additions was 12.93%, indicating stronger financial health [11]. Valuation and Performance Comparison - The average price-to-earnings (PE) ratio for stocks added to the index was significantly lower than those removed, suggesting improved valuation metrics [13]. - The average dividend yield for new additions increased by 36 basis points compared to those removed, reflecting a more attractive income potential [13]. Conclusion - The adjustments to the CSI Dividend Index are expected to enhance its dividend yield and overall quality, while also reducing the PE ratio, thereby maintaining its long-term investment value [15].

Core Points - The Shanghai Composite Index closed at 3875.26 points, above the annual line, with a change of 0.29% [1] - The total trading volume of A-shares reached 1,723.17 billion yuan [1] - A total of 87 A-shares have surpassed the annual line today, with notable stocks showing significant deviation rates [1] Summary by Category Stock Performance - Qingniao Firefighting (002960) saw a price increase of 10.03% with a deviation rate of 9.78% [1] - Tianyi New Materials (688033) increased by 20.04%, with a deviation rate of 7.79% [1] - Liande Equipment (300545) rose by 20.01%, showing a deviation rate of 6.16% [1] Trading Activity - The trading turnover rate for Qingniao Firefighting was 2.39% [1] - Tianyi New Materials had a turnover rate of 12.35% [1] - Liande Equipment recorded a turnover rate of 19.65% [1] Annual Line Breakthroughs - The stocks with the largest deviation rates from the annual line include: - Qingniao Firefighting: 9.78% [1] - Tianyi New Materials: 7.79% [1] - Liande Equipment: 6.16% [1] - Other stocks that just crossed the annual line include: - China Merchants Port, Aotai Biological, and Rongtai Health, with smaller deviation rates [1]

Core Viewpoint - The company, Aotai Biology, reported that as of October 31, 2025, the total number of shareholders is 5,665 [1] Summary by Categories - **Company Information** - Aotai Biology has a total of 5,665 shareholders as of the specified date [1]

Meeting Overview - The second extraordinary general meeting of shareholders was held on November 25, 2025, at the company's conference room in Hangzhou, Zhejiang Province [2] - The total share capital as of the meeting's registration date was 79,280,855 shares, with 973,631 shares in the company's repurchase account not entitled to vote [2] Voting and Attendance - The meeting was convened by the board of directors and chaired by Mr. Gao Fei, utilizing a combination of on-site and online voting methods [4] - All five current directors and three current supervisors attended the meeting, along with the board secretary [4] Resolutions Passed - The following resolutions were approved: - Cancellation of the supervisory board and amendments to the Articles of Association [5] - Revisions to various internal management systems, including: - Shareholders' meeting rules - Board meeting rules - Independent director work system - Related party transaction management system - Prevention of related party fund occupation management system - External guarantee management system - External investment management system - Cumulative voting implementation details - Fundraising management measures [6][7] Legal Compliance - The meeting was witnessed by Shanghai Lifeng Law Firm, confirming that the convening, holding, and voting procedures complied with relevant laws and regulations [8]

Core Points - The company announced the election of Mr. Gao Yuecan as the employee representative director of the third board of directors during the second meeting of the third employee representative assembly held on November 25, 2025 [2]

证券代码：688606 证券简称：奥泰生物 公告编号：2025-054 杭州奥泰生物技术股份有限公司 关于完成董事增选的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、选举独立董事的情况 杭州奥泰生物技术股份有限公司（以下简称"公司"）于2025年10月30日召开了 第三届董事会第十七次会议，审议通过了《关于增选第三届董事会独立董事的议案》， 公司董事会同意提名陈善基先生为公司第三届董事会独立董事，任期自股东大会审议 通过之日起至第三届董事会任期届满之日止。具体内容详见公司于2025年10月31日在 上海证券交易所网站（www.sse.com.cn）披露的《关于增选第三届董事会独立董事的 公告》（公告编号：2025-051）。 2025年11月25日，公司召开了2025年第二次临时股东大会，增选陈善基先生为公 司第三届董事会独立董事，任期自本次股东大会审议通过之日起至第三届董事会任期 届满之日止。 二、选举职工董事的情况 根据《中华人民共和国公司法》（以下简称"《公司法》"）和修订后的《杭州 奥泰生物技术股份有限 ...

证券代码：688606 证券简称：奥泰生物 公告编号：2025-055 杭州奥泰生物技术股份有限公司 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 （二） 股东大会召开的地点：浙江省杭州市钱塘区下沙街道乔新路 383 号公司 会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 66 | | --- | --- | | 普通股股东人数 | 66 | | 2、出席会议的股东所持有的表决权数量 | 52,995,653 | | 普通股股东所持有表决权数量 | 52,995,653 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 67.6766 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 67.6766 | 注：截至本次股东大会股权登记日的总股本为 79,280,855 股；其中公司回购专用 ...

2025 年第二次临时股东大会的法律意见书 致：杭州奥泰生物技术股份有限公司 上海礼丰律师事务所(以下简称"本所")接受杭州奥泰生物技术股份有限公司 (以下简称"公司")的委托，指派本所律师(以下简称"本所律师")根据《中华人民共 和国证券法》《中华人民共和国公司法》《上市公司股东会规则》等法律、法规、 规范性文件(以下统称"法律法规")及《杭州奥泰生物技术股份有限公司章程》(以 下简称"公司章程")的规定就公司 2025 年第二次临时股东大会(以下简称"本次股 东大会")相关事宜出具法律意见。 本所及经办律师依据《中华人民共和国证券法》《律师事务所从事证券法律 业务管理办法》和《律师事务所证券法律业务执业规则(试行)》等规定及法律意 见书出具日以前已经发生或者存在的事实，严格履行了法定职责，遵循了勤勉尽 责和诚实信用原则，进行了充分的核查验证，保证法律意见所认定的事实真实、 准确、完整、及时，所发表的结论性意见合法、准确，不存在虚假记载、误导性 陈述或者重大遗漏，并承担相应法律责任。 本所律师已经按照有关法律法规的要求和律师行业公认的道德标准以及勤 勉尽责的精神对公司本次股东大会相关文件及事实进行了审查和验 ...

Core Viewpoint - On November 21, Aotai Bio experienced a decline of 2.99% with a trading volume of 24.0661 million yuan, indicating a potential shift in investor sentiment and market dynamics [1]. Financing Summary - On November 21, Aotai Bio had a financing buy-in amount of 3.1237 million yuan and a financing repayment of 2.8837 million yuan, resulting in a net financing buy of 240,000 yuan [1]. - As of November 21, the total financing and securities lending balance for Aotai Bio was 86.7704 million yuan, which accounts for 1.68% of its circulating market value, indicating a high level of financing activity compared to the past year [1]. - The financing balance of 86.7704 million yuan exceeds the 70th percentile level over the past year, suggesting a relatively high position in terms of financing [1]. Shareholder and Financial Performance Summary - As of October 31, Aotai Bio had 5,665 shareholders, a decrease of 1.29% from the previous period, while the average circulating shares per person increased by 1.31% to 13,994 shares [2]. - For the period from January to September 2025, Aotai Bio reported a revenue of 633 million yuan, reflecting a year-on-year growth of 2.44%, while the net profit attributable to shareholders decreased by 3.91% to 190 million yuan [2]. Dividend and Institutional Holdings Summary - Aotai Bio has distributed a total of 1.28 billion yuan in dividends since its A-share listing, with 955.6 million yuan distributed over the past three years [3]. - As of September 30, 2025, among the top ten circulating shareholders, Hong Kong Central Clearing Limited held 2.1873 million shares, a decrease of 387,400 shares from the previous period, while Guotai Junan Value Advantage Flexible Allocation Mixed A (000362) entered the top ten as the ninth largest shareholder with 713,300 shares [3].